June 25, 2021

Upfront Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Setting a new benchmark for control arm estimates

650×450-Prostate-Cancer

The phase 3 SWOG S1216 trial has set a new benchmark for survival estimates for metastatic hormone-sensitive prostate cancer (mHSPC) patients who have access to multiple approved subsequent life-prolonging therapies, according to findings presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“At the time this study was being designed, the only option for mHSPC patients was androgen deprivation therapy,” notes study co-chair Shilpa Gupta, MD, Department of Hematology and Medical Oncology, Cleveland Clinic. “The aim of this trial was to determine how best to improve the outcomes of these patients with upfront treatment intensification.”

To accomplish this, the research team set out to explore the benefits of the novel agent TAK-700, an oral selective nonsteroidal 17, 20-lyase inhibitor, compared with bicalutamide — a drug that received FDA approval in the last few years, according to Dr. Gupta.

Cohort and results

The study enrolled patients with newly diagnosed mHSPC with distant metastatic disease, a Zubrod performance status of 0-2, and a PSA of ≥ 2 ng/ml. They were randomized 1:1 to receive androgen deprivation therapy plus TAK-700 (300 mg twice daily) or androgen deprivation therapy plus bicalutamide (50 mg daily).

The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), PSA at seven months and adverse event profile. From March 2013 to July 2017, researchers randomized 1,313 patients, and 1,279 were included in the intention-to-treat analysis. The median age of study participants was 68 years, and 10% of subjects were Black. The median PSA was 3030 ng/mL, and 49% had extensive disease.

Advertisement

As of March 2021, 192 (30.1%) patients remained on treatment in the TAK-700 arm compared with 100 (15.6%) in the bicalutamide cohort. The researchers reported 525 deaths, which met the requirement for the final OS analysis.

After a median follow-up of 4.9 years, the data showed a significant improvement in PFS and PSA response with TAK-700 compared with bicalutamide. However, the researchers observed no improvement in OS. An improvement in median OS of approximately 11 months with TAK-700 treatment versus bicalutamide did not meet the prespecified criteria for statistical significance.

More grade 3/4 adverse events were reported in patients who received TAK-700 compared with those who underwent treatment with bicalutamide (43% vs. 14%). These included hypertension (20% vs. 5%) and fatigue (5% vs. 2%).

Setting a new benchmark

Importantly, the median OS of 70 months in the control arm is 16 months higher than originally estimated and the highest among any other contemporary phase III trial in this patient population.

Advertisement

This sets a new benchmark for what the estimates should be for control arms in such trials as well as counseling patients on survival estimates,” says Dr. Gupta. “This study has not only shown us that treatment intensification upfront is very important compared with androgen deprivation therapy alone, but it also highlights that men with hormone-sensitive prostate cancer who receive subsequent life-prolonging therapies are living much longer than previously expected.

“And so, when designing new trials, we have to keep that in mind in terms of what benefit to expect or how to make it clinically meaningful,” she concludes. “This trial was a huge endeavor by the entire team and NCI and provides valuable information. Correlative and biomarker-based work is currently underway to identify biomarkers of response and resistance.”

Related Articles

22-CNR-IV-Drip-CQD-Hero-650×450-1
April 20, 2022
Combination Chemo-Immunotherapy Appears to Improve Outcomes in Muscle-Invasive Bladder Cancer

New results from the BLASST-1 trial show increases in downstaging and relapse-free survival

Mammary carcinoma with lobular features. Breast cancer
April 12, 2022
MRI May Be Best Tool for Tumor Staging and Detecting Bilateral Disease in Invasive Lobular Carcinoma

Study highlights value of preoperative imaging to guide surgical decision-making

rt-breast_650x450
July 1, 2021
Designing an Optimal Breast Cancer Radiation Protocol

How a novel tissue marker makes a difference

PrimaryPulmonaryCarcinoid
June 29, 2021
Achieving Cost-Effectiveness with Adjuvant Osimertinib for NSCLC

Model identifies target OS at which economic benefits of treatment outpace placebo

650×450-bladder
May 24, 2021
Combination Maintenance Therapy in Metastatic Urothelial Cancer

In search of improved outcomes for patients

650×450-Prostate-GettyImages-580120508_New Header_17-URL-680
May 12, 2021
Innovations in Prostate Cancer Care

An overview of our leading-edge diagnostics and therapeutics

Ad